ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

BioNTech, Moderna and Pfizer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

BioNTech×Moderna×Pfizer×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BioNTechModernaPfizer
studies on the registry1241194,073
open to participants now3218147
phase 3 studies under way9299
reach primary completion within a year111693
programswith a study of their own in two years231691+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBioNTechModernaPfizer
Phase 1

BioNTech: 4 of its 23 programs at phase 1

  1. BNT168phase 1
  2. BNT3219phase 1
  3. BNT351phase 1
  4. CV09070101phase 1
17%

Moderna: 5 of its 16 programs at phase 1

  1. MRNA-1365phase 1
  2. MRNA-1469phase 1
  3. mRNA-1519phase 1
  4. MRNA-4106phase 1
  5. MRNA-4200phase 1
31%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%
Phase 265%31%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%
Phase 3

BioNTech: 3 of its 23 programs at phase 3

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3
  3. trastuzumab pamirtecanphase 3
13%

Moderna: 3 of its 16 programs at phase 3

  1. mRNA-1345 respiratory syncytial virus vaccinephase 3
  2. MRNA-1018phase 3
  3. MRNA-1083phase 3
19%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%
Approved, new studies

BioNTech: 1 of its 23 programs at approved, new studies

  1. BNT162 Vaccineapproved, new study
4%

Moderna: 3 of its 16 programs at approved, new studies

  1. 2019-nCoV Vaccine mRNA-1273approved, new study
  2. MRNA-1283approved, new study
  3. mRNA-1010 influenza vaccineapproved, new study
19%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
BioNTech4 readouts · 1 phase 3

BioNTech, Nov ’26: 1 program whose next study reaches primary completion

  1. BNT351phase 1 · Nov 0 · NCT07392372
·

BioNTech, Jan ’27: 1 program whose next study reaches primary completion

  1. pumitamigphase 3 · Jan 1 · NCT05879055
··

BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. BNT162 Vaccineapproved, new study · Apr 12 · NCT07798648
·

BioNTech, Jun ’27: 1 program whose next study reaches primary completion

  1. BNT166Aphase 2 · Jun 0 · NCT07379580
····
Moderna9 readouts · 4 phase 3·

Moderna, Dec ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. mRNA-1010 influenza vaccineapproved, new study · Dec 7 · NCT07884175
  2. 2019-nCoV Vaccine mRNA-1273approved, new study · Dec 11 · NCT07863635
  3. MRNA-1283approved, new study · Dec 11 · NCT07863635

Moderna, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. MRNA-1018phase 3 · Jan 28 · NCT07496450
···

Moderna, May ’27: 1 program whose next study reaches primary completion

  1. Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189phase 2 · May 15 · NCT07478952
·

Moderna, Jul ’27: 1 program whose next study reaches primary completion

  1. MRNA-1365phase 1 · Jul 20 · NCT07764237

Moderna, Aug ’27: 2 programs whose next study reaches primary completion

  1. MRNA-4106phase 1 · Aug 3 · NCT06880549
  2. MRNA-4200phase 1 · Aug 3 · NCT06880549

Moderna, Sep ’27: 1 program whose next study reaches primary completion

  1. MRNA-1469phase 1 · Sep 30 · NCT07737717
·
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

BioNTech

New programs 2

  • BNT3219phase 1 · first study · Oct 19
  • BNT3210phase 2 · first study · Oct 15

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Moderna

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBioNTechModernaPfizer
Influenza, Humanall three · compare here

Pfizer in Influenza, Human: 3 programs

  1. abrysvophase 3
  2. qIRVphase 1
  3. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Influenza, Human in search

COVID-19all three · compare here

BioNTech in COVID-19: 1 program

  1. BNT162 Vaccineapproved, new study

Their studies: BioNTech’s studies of COVID-19 in search

Moderna in COVID-19: 3 programs

  1. MRNA-1083phase 3
  2. 2019-nCoV Vaccine mRNA-1273approved, new study
  3. MRNA-1283approved, new study

Their studies: Moderna’s studies of COVID-19 in search

Pfizer in COVID-19: 5 programs

  1. abrysvophase 3
  2. ibuzatrelvirphase 3
  3. zavegepantphase 3
  4. remdesivirphase 3
  5. PA-001phase 1

Their studies: Pfizer’s studies of COVID-19 in search

Neoplasm Metastasisall three · compare here

BioNTech in Neoplasm Metastasis: 1 program

  1. trastuzumab pamirtecanphase 3

Their studies: BioNTech’s studies of Neoplasm Metastasis in search

Moderna in Neoplasm Metastasis: 2 programs

  1. MRNA-4106phase 1
  2. MRNA-4200phase 1

Their studies: Moderna’s studies of Neoplasm Metastasis in search

Pfizer in Neoplasm Metastasis: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Neoplasm Metastasis in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

BioNTech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. pumitamigphase 3
  2. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Carcinoma, Non-Small-Cell Lung in search

–

Pfizer in Carcinoma, Non-Small-Cell Lung: 9 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 4 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasms2 of 3 · compare here

BioNTech in Breast Neoplasms: 3 programs

  1. pumitamigphase 3
  2. trastuzumab pamirtecanphase 3
  3. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Breast Neoplasms in search

–

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Colorectal Neoplasms2 of 3 · compare here–

Pfizer in Colorectal Neoplasms: 4 programs

  1. tivunatamigphase 3
  2. tusamitamab sonditecanphase 1
  3. tucatinibapproved, new study
  4. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Colorectal Neoplasms in search

Melanoma2 of 3 · compare here

BioNTech in Melanoma: 1 program

  1. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Melanoma in search

–
Pneumococcal Infections2 of 3 · compare here

BioNTech in Pneumococcal Infections: 1 program

  1. BNT162 Vaccineapproved, new study

Their studies: BioNTech’s studies of Pneumococcal Infections in search

–

Pfizer in Pneumococcal Infections: 4 programs

  1. PG4phase 3
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3
  3. PG4 Multivalent Vaccinephase 3
  4. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Pneumococcal Infections in search

Small Cell Lung Carcinoma2 of 3 · compare here

BioNTech in Small Cell Lung Carcinoma: 2 programs

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3

Their studies: BioNTech’s studies of Small Cell Lung Carcinoma in search

–

Pfizer in Small Cell Lung Carcinoma: 3 programs

  1. tivunatamigphase 3
  2. mevrometostatphase 3
  3. tegtociclibphase 2

Their studies: Pfizer’s studies of Small Cell Lung Carcinoma in search

Endometrial Neoplasms2 of 3 · compare here

BioNTech in Endometrial Neoplasms: 1 program

  1. trastuzumab pamirtecanphase 3

Their studies: BioNTech’s studies of Endometrial Neoplasms in search

–

Pfizer in Endometrial Neoplasms: 1 program

  1. tivunatamigphase 3

Their studies: Pfizer’s studies of Endometrial Neoplasms in search

Lyme Disease2 of 3 · compare here–

Moderna in Lyme Disease: 1 program

  1. MRNA-1982phase 2

Their studies: Moderna’s studies of Lyme Disease in search

Pfizer in Lyme Disease: 1 program

  1. VLA15phase 3

Their studies: Pfizer’s studies of Lyme Disease in search

Multiple Myeloma2 of 3 · compare here–

Moderna in Multiple Myeloma: 1 program

  1. mRNA-based T-cell Engager mRNA-2808phase 2

Their studies: Moderna’s studies of Multiple Myeloma in search

Pfizer in Multiple Myeloma: 1 program

  1. elranatamabapproved, new study

Their studies: Pfizer’s studies of Multiple Myeloma in search

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: BioNTech 11 of 23 · Moderna 5 of 16 · Pfizer 67 of 91 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).